These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31391186)

  • 1. YES1 Is a Targetable Oncogene in Cancers Harboring
    Hamanaka N; Nakanishi Y; Mizuno T; Horiguchi-Takei K; Akiyama N; Tanimura H; Hasegawa M; Satoh Y; Tachibana Y; Fujii T; Sakata K; Ogasawara K; Ebiike H; Koyano H; Sato H; Ishii N; Mio T
    Cancer Res; 2019 Nov; 79(22):5734-5745. PubMed ID: 31391186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Cancer Therapy: YES1 Is the New Kid on the Block.
    Rai K
    Cancer Res; 2019 Nov; 79(22):5702-5703. PubMed ID: 31772072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
    Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Fan PD; Narzisi G; Jayaprakash AD; Venturini E; Robine N; Smibert P; Germer S; Yu HA; Jordan EJ; Paik PK; Janjigian YY; Chaft JE; Wang L; Jungbluth AA; Middha S; Spraggon L; Qiao H; Lovly CM; Kris MG; Riely GJ; Politi K; Varmus H; Ladanyi M
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):E6030-E6038. PubMed ID: 29875142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YES1 Is a Druggable Oncogenic Target in SCLC.
    Redin E; Garrido-Martin EM; Valencia K; Redrado M; Solorzano JL; Carias R; Echepare M; Exposito F; Serrano D; Ferrer I; Nunez-Buiza A; Garmendia I; García-Pedrero JM; Gurpide A; Paz-Ares L; Politi K; Montuenga LM; Calvo A
    J Thorac Oncol; 2022 Dec; 17(12):1387-1403. PubMed ID: 35988891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
    Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
    Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
    JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
    Kook E; Chun KS; Kim DH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YES1: A Novel Therapeutic Target and Biomarker in Cancer.
    Garmendia I; Redin E; Montuenga LM; Calvo A
    Mol Cancer Ther; 2022 Sep; 21(9):1371-1380. PubMed ID: 35732509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation.
    Zhao D; Yin Z; Soellner MB; Martin BR
    Cell Chem Biol; 2021 Aug; 28(8):1235-1241.e5. PubMed ID: 33730553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of YES1 signaling in tumor therapy resistance.
    Zhou H; Sun D; Tao J; Xu M; Zhang X; Hou H
    Cancer Innov; 2023 Jun; 2(3):210-218. PubMed ID: 38089407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Patel PR; Sun H; Li SQ; Shen M; Khan J; Thomas CJ; Davis MI
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4398-403. PubMed ID: 23787099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.
    Choi YJ; Choi M; Park J; Park M; Kim MJ; Lee JS; Oh SJ; Lee YJ; Shim WS; Kim JW; Kim MJ; Kim YC; Kang KW
    Biomed Pharmacother; 2024 Feb; 171():116124. PubMed ID: 38198957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
    Chen L; Cao H; Feng Y
    World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1.
    Tan W; Lim SG; Tan TM
    World J Gastroenterol; 2015 Dec; 21(46):13030-41. PubMed ID: 26676187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.
    Liu L; Yang J; Zhu X; Li D; Lv Z; Zhang X
    FEBS J; 2016 Jun; 283(12):2326-39. PubMed ID: 27093644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
    Wang W; Marsh S; Cassidy J; McLeod HL
    Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.
    Bilal E; Alexe G; Yao M; Cong L; Kulkarni A; Ginjala V; Toppmeyer D; Ganesan S; Bhanot G
    Genes Cancer; 2010 Oct; 1(10):1063-73. PubMed ID: 21779430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.